πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors β€” phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β€” searchable for business development and competitive intelligence.

1,041 results for β€œAdvanced” Clear

  1. Phase I Study of PM534 to Patients with Advanced Solid Tumors

    Lacuna Pharma Pty Ltd

    Advances solid tumors

    phase 2 other active

    1 trial

  2. Phase I, Open-label, Dose-escalating, Clinical and Pharmacokinetic Study of PM14 Administered Intravenously to Patients with Advanced Solid Tumors

    Lacuna Pharma Pty Ltd

    Advanced Solid Tumors

    phase 2 other active

    1 trial

  3. Phase I/II First-In-Human open-label trial to assess safety and efficacy of STX-241 in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) resistant to EGFR tyrosine kinase inhibitors (TKIs)

    Pierre Fabre Medicament

    locally advanced or metastatic non-small cell lung cancer (NSCLC) resistant to EGFR tyrosine kinase inhibitors (TKIs)

    phase 2 other active

    1 trial

  4. Probiotics Compound (Biolosion)

    Sun Yat-sen University

    Advanced Urothelial Carcinoma

    phase 2 small molecule active

    1 trial

  5. Programmed Cell Death Protein 1 Inhibitor

    Chinese University of Hong Kong

    Locally Advanced Esophageal Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  6. QINLOCK 50 mg tablets

    Lacuna Pharma Pty Ltd

    Advanced gastrointestinal stromal tumor (GIST)

    phase 2 small molecule active

    1 trial

  7. QL1706

    The First People's Hospital of Lianyungang

    Local Advanced Esophageal Cancer

    phase 2 small molecule active

    1 trial

  8. REGN7075

    Regeneron UK Limited

    Advanced Solid Tumors

    phase 2 small molecule active

    1 trial

  9. RO7790118, RO7791094, RO7790118, Tiragolumab, Avastin 25 mg/ml concentrate for solution for infusion., RO7247669, Tecentriq 1 200 mg concentrate for solution for infusion, RO7790118, TPST-1120, ADG126, RoActemra 20 mg/mL concentrate for solution for infusion

    Hoffmann-La Roche

    Advanced liver cancers

    phase 2 small molecule active

    1 trial

  10. Radiation: Radiation TherapyοΌ›Biological: Personalized tumor peptide vaccine

    Hospital Authority, Hong Kong

    Advanced Tumors

    phase 2 other active

    1 trial

  11. Raludotatug Deruxtecan

    Daiichi Sankyo

    Advanced/metastatic solid tumors including gynecological cancers (endometrial cancer, cervical cancer, and nonhigh- grade serous ovarian cancer) and genitourinary cancers (urothelial cancer and ccRCC)

    phase 2 small molecule active

    1 trial

  12. Recombinant Human Endostatin Injection

    The First People's Hospital of Lianyungang

    Locally Advanced Squamous Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  13. Repotrectinib (TPX-0005)

    Turn Therapeutics

    Advanced Solid Tumors

    phase 2 small molecule active

    1 trial

  14. Repotrectinib (TPX-0005), Repotrectinib (TPX-0005), Repotrectinib (TPX-0005)

    Turn Therapeutics

    Advanced solid tumors

    phase 2 small molecule active

    1 trial

  15. Rilvegostomig, Rilvegostomig

    AstraZeneca AB

    Advanced Non-small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer, stage III unresectable Non-small Cell Lung Cancer (Protocol Parts A-B), stage IV Non-small Cell Lung Cancer (Protocol Parts A-E).

    phase 2 small molecule active

    1 trial

  16. Rozlytrek 200 mg hard capsules

    Hoffmann-La Roche

    Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

    phase 2 small molecule active

    1 trial

  17. Rubraca 300 mg film-coated tablets, Rubraca 200 mg film-coated tablets, BEVACIZUMAB, Rubraca 250 mg film-coated tablets, CARBOPLATIN, PACLITAXEL

    Fondazione Telethon ETS

    Advanced (stage III B-C-IV) ovarian, primary peritoneal and Fallopian tube cancer.

    phase 2 small molecule active

    1 trial

  18. S-1

    United Therapeutics Europe Ltd

    Locally Advanced or Metastatic Pancreatic Cancer

    phase 2 small molecule completed

    1 trial

  19. S-1

    United Therapeutics Europe Ltd

    Advanced Non-Small Cell Lung Cancer

    phase 2 small molecule completed

    2 trials

  20. S095029/Sym025, LIBTAYO 350 mg concentrate for solution for infusion., S095018/Sym023, S095024/Sym024

    The George Institute

    Non-small cell lung cancer (NSCLC): - Locally advanced NSCLC where participants are not candidates for surgical resection and/or definitive chemoradiation, or - Metastatic NSCLC

    phase 2 small molecule active

    1 trial

  21. SDREGN2810

    Regeneron UK Limited

    Advanced Non-Small Cell Lung Carcinoma

    phase 2 small molecule terminated

    1 trial

  22. SELPERCATINIB, SELPERCATINIB

    Wuhan Createrna Science and Technology Co., Ltd

    Male or female patients age 12 years or older with a locally advanced or metastatic solid tumor with evidence of a RET gene alteration in tumor and/or blood.

    phase 2 small molecule active

    1 trial

  23. SELPERCATINIB, Selpercatinib, Selpercatinib, SELPERCATINIB, Selpercatinib

    Wuhan Createrna Science and Technology Co., Ltd

    Pediatric Patients with Advanced RET-Altered Solid or Primary Central Nervous System Tumors

    phase 2 small molecule active

    1 trial

  24. SKB103 for injection monotherapy

    Sichuan Provincial People's Hospital

    Advanced Solid Tumors

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β€” verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources